We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium.
- Authors
Yardley, Denise A; Burris, Howard A, 3rd; Clark, Bobby L; Shipley, Dianna; Rubin, Mark; Barton, John, Jr; Arrowsmith, Edward; Hainsworth, John D
- Abstract
Preclinical models suggest that addition of anti-vascular endothelial growth factor therapy may improve the efficacy of anti-estrogens in hormone-sensitive breast cancer. This phase II trial evaluated the feasibility and efficacy of bevacizumab added to either anastrozole or fulvestrant in the first-line treatment of patients who have hormone receptor-positive metastatic breast cancer.
- Publication
Clinical breast cancer, 2011, Vol 11, Issue 3, p146
- ISSN
1938-0666
- Publication type
Journal Article
- DOI
10.1016/j.clbc.2011.03.010